a random-effects study-level meta-analysis, and a meta-regression analysis of covariates of interest. We examined the risk of publication bias using the fail-safe test. Results: In a pooled analysis of studies from the 3 separate meta-analyses, we identified a total of 51 LAI treatment arms, including 13,071 individuals (mean age=38.8 ± 6.2, 60.5 ± 11.9% male, illness duration=12.1 ± 5.7 years, mean total PANSS score=74.3 ± 7.8). The mean planned follow-up duration was 71.5 ± 37.0 (range=24-154) weeks, and the defined daily dose (DDD) of LAI treatment was 1.1. The pooled weighted relapse rate in a random effects model was 28% (95% CI=24-31%), being 22% (95% CI=15-30%) in RCTs (mean duration= 66.2 wks), 33.0% (95% CI=24-43%) in mirror image studies (mean duration= 55.4 wks), and 30% (95% CI=26-34%) in naturalistic cohort studies (mean duration= 79.4 wks). In a meta-regression analysis, RCT design (p=0.04), and industry sponsorship (p=0.03) were associated with lower relapse rates on LAI treatment, whereas studies conducted in Europe (p=0.03) or North America (p<0.01), and longer duration of follow-up (p<0.01) were associated with greater relapse rates. In the fail-safe test, we found that we would need 4,629 studies to bring the p Value>α, suggesting low risk of bias. Discussion: About one in four individuals receiving LAI treatment relapsed according to study definitions, suggesting that this is a relatively common phenomenon, even during assured medication adherence. At the study level, no major differences were observed in terms of sociodemographic characteristics, type of drugs, mean drug daily dose, or baseline severity at study entry in relation to relapse rate in individuals treated with LAIs. The relapse rate though was lower in RCTs, which could reflect a difference in the patient population participating and/or the nature of observation in LAI RCTs. These results suggest either that the examined study design, illness severity and treatment related covariates are limited to identify potential mediators and moderators of BAMM, or that the data about the covariates at the study level was not precise enough to detect clinical characteristics associated with BAMM. Given the relative frequency of BAMM, future research should explore potential mediators and moderators of the failure to maintain response to antipsychotic treatment even during periods of assured adherence. Neurobiological markers, which may be more closely related to the pathophysiology of BAMM, and individual participant data meta-analyses, which can identify clinical predictors with greater precision, should be the next steps.
a random-effects study-level meta-analysis, and a meta-regression analysis of covariates of interest. We examined the risk of publication bias using the fail-safe test. Results: In a pooled analysis of studies from the 3 separate meta-analyses, we identified a total of 51 LAI treatment arms, including 13,071 individuals (mean age=38.8 ± 6.2, 60.5 ± 11.9% male, illness duration=12.1 ± 5.7 years, mean total PANSS score=74.3 ± 7.8). The mean planned follow-up duration was 71.5 ± 37.0 (range=24-154) weeks, and the defined daily dose (DDD) of LAI treatment was 1.1. The pooled weighted relapse rate in a random effects model was 28% (95% CI=24-31%), being 22% (95% CI=15-30%) in RCTs (mean duration= 66.2 wks), 33.0% (95% CI=24-43%) in mirror image studies (mean duration= 55.4 wks), and 30% (95% CI=26-34%) in naturalistic cohort studies (mean duration= 79.4 wks). In a meta-regression analysis, RCT design (p=0.04), and industry sponsorship (p=0.03) were associated with lower relapse rates on LAI treatment, whereas studies conducted in Europe (p=0.03) or North America (p<0.01), and longer duration of follow-up (p<0.01) were associated with greater relapse rates. In the fail-safe test, we found that we would need 4,629 studies to bring the p Value>α, suggesting low risk of bias. Discussion: About one in four individuals receiving LAI treatment relapsed according to study definitions, suggesting that this is a relatively common phenomenon, even during assured medication adherence. At the study level, no major differences were observed in terms of sociodemographic characteristics, type of drugs, mean drug daily dose, or baseline severity at study entry in relation to relapse rate in individuals treated with LAIs. The relapse rate though was lower in RCTs, which could reflect a difference in the patient population participating and/or the nature of observation in LAI RCTs. These results suggest either that the examined study design, illness severity and treatment related covariates are limited to identify potential mediators and moderators of BAMM, or that the data about the covariates at the study level was not precise enough to detect clinical characteristics associated with BAMM. Given the relative frequency of BAMM, future research should explore potential mediators and moderators of the failure to maintain response to antipsychotic treatment even during periods of assured adherence. Neurobiological markers, which may be more closely related to the pathophysiology of BAMM, and individual participant data meta-analyses, which can identify clinical predictors with greater precision, should be the next steps. Background: Impairments in self-assessment are commonly found in people with schizophrenia and impairments in introspective accuracy (IA) predict impaired functional outcome. previous studies have suggested mis-estimation of cognitive and functional skills predict impairment in everyday functioning at least as much as ability scores. In this study, we examined self-assessment of social cognitive ability and related these self-assessments to assessments of social cognition from informants, to performance on tests of social cognitive ability, and to everyday outcomes. The difference between self-reported social cognitive abilities and informant ratings was our measure of IA. Methods: People with schizophrenia (n=135) performed 8 tests of social cognitive abilities. They also rated their social cognitive abilities on the Observable Social Cognition Rating Scale (OSCARs). High contact informants also rated social cognitive ability and everyday outcomes, while unaware of the patients' other scores. Social competence was also measured with a performance-based assessment and clinical ratings of negative symptoms were also performed. Results: Patient reports of their social cognitive abilities were uncorrelated with performance on social cognitive tests and with three of the four domains of everyday functional outcomes. IA, in specific overestimation of performance compared to informant ratings, predicted impaired everyday functioning across all four functional domains. IA scores predicted functional outcomes even when the influences of social cognitive performance, social competence, and negative symptoms were considered in regression models. Thus, self-assessment of social cognition had a relatively specific impact social outcomes. Discussion: Mis-estimation of social cognitive ability was a more important predictor of social and nonsocial outcomes in schizophrenia than performance on social cognitive tests. These results suggest that consideration of IA is critical when attempting to assess causes of everyday disability and when implementing interventions aimed at disability reduction. Background: Information and interventions for mental illness are increasingly being provided on-line. There is an expectation that citizens have access to the internet and are competent in using technology. People with schizophrenia are often excluded from social engagement, have cognitive impairment and have very limited income; all of which may reduce their use of technology. This project aimed to assess the use of technology and the internet in people with schizophrenia or schizoaffective disorder, living in the community. Methods: Face-to-face structured interviews were used to evaluate technology literacy, attitudes towards technology, and access and engagement with technology in 50 people with schizophrenia or schizoaffective disorder aged 18-65 years, living in the community. Results: About half of the study population had access to a computer, and half had access to the internet at home. Participants' most common uses of technology were voice-calling, messaging, surfing the internet and accessing Facebook. The use of more advanced functions of technology (calendar, banking, news, health information) were rare. The general attitude among participants was that technology was not a significant part of their lives. Discussion: Technology literacy and internet access were limited in this population. This needs to be addressed before the on-line delivery of educational information, service information and e-health interventions can be widely utilised in people with schizophrenia. Background: In the European Union approximately 5 million people suffer from psychotic disorders. Patients with schizophrenia make up the largest subgroup of these, and between 30-50% of them are considered resistant to treatment. Despite the proven potential of m-health solutions, there remains a lack of technological solutions in the treatment of patients with this disease. To improve the quality of care of these outpatients, an m-health solution termed Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia (m-RESIST) has been created in European Union and implemented in three countries (Spain, Hungary and Israel). m-RESIST is an innovative project aimed to empower patients with Treatment Resistant Schizophrenia, which integrates pharmacological and psychosocial approaches, develops knowledge of the illness using predictive models, and includes the following m-Health tools: a Dashboard, a Smartwatch and a Smartphone. Prior to the implementation in the healthcare reality, the solution has been tested in pilot groups to assess the acceptability, usability and satisfaction of all m-RESIST components in each country. In addition to online and onsite visits, this phase has included an anonymous online questionnaire, with the aim of capturing more consistently the opinion of participants in their experience with m-RESIST. We summarize their opinions about services and devices included in the solution, as well as the improvement proposals of each group. Methods: During three months (from August to October), a case manager from Spain sent out an interval question to the Spanish participants via m-RESIST Dashboard, in order to collect information about the users experience with the system. It was administered weekly on different days and at different times, being anonymous for both parts. We have obtained qualitative information from nine patients, one caregiver and two clinicians. Results: Patients consider m-RESIST a useful tool, in terms of immediacy of contact with clinicians, improvement of disease awareness, better follow-up of their disease, less-worries from caregivers and feeling protected by having a team with whom they can share their concerns. As cons, patients have a strong feeling of being observed and with too much repetitive questionnaires to answer. They consider a bit difficult to use the devices, with several errors in its operation. They do not like to carrying the smartwatch and to check the battery of the devices. Also, the program is not available on weekends, which leads to a feeling of being somehow disregarded. For patients, this solution should also include the possibility of changing programmed location when on vacations and it should not be a substitute for traditional treatment. Regarding caregivers, m-RESIST is considered as a good tool to have in their daily lives, because it helps in terms of disease improvement, to have a better follow-up about pharmacological issues and symptoms, and to feel secure knowing there is a support for both patient and caregiver. No cons were reported. For clinicians, m-RESIST is a system with high potential, being easy, intuitive and useful, specially to share psychoeducational content with patients and to improve communication with them. However, several technological problems must be solved in the future, there still provide a poor patient monitoring and much more time is needed than regarding the traditional treatment. Discussion: The three user groups consider m-RESIST as a useful tool, with pros and cons being described regarding their specific needs and provided proposals for improvement.
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